课题基金 / 基金详情

(131) IODINE-B1 RADIOIMMUNOTHERAPY OF ADVANCED NONHODGKIN'S LYMPHOMA

(131) IODINE-B1 RADIOIMMUNOTHERAPY OF ADVANCED NONHODGKIN'S LYMPHOMA
(131) 晚期非霍奇金淋巴瘤的碘 B1 放射免疫治疗
批准号：
6274632
负责人：
MARK S. KAMINSKI
金额：
$2.15万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6274632
关键词：
B cell lymphoma CD antigens clinical research combination cancer therapy dosage drug adverse effect drug screening /evaluation human subject human therapy evaluation iodine monoclonal antibody neoplasm /cancer immunotherapy neoplasm /cancer radiation therapy nonHodgkin's lymphoma radiotracer

项目摘要

项目成果

MARK S. KAMINSKI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The main purpose of this study is to determine the tumor response rate of a maximally tolerated radioimmunotherapeutic dose of a monoclonal anti-CD20 antibody labeled with 131-I in patients with B-cell lymphoma who have relapsed after or have failed to respond to conventional-dose chemotherapy. Other goals are to assess the tumor targeting potential and the toxicity of this radiolabeled anti-B-cell antibody.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RETREATMENT OF NON HODGKINS LYMPHOMA W/ IODINE 131 ANTI B1 ANTIBODY
I 131 ANTI B1 ANTIBODY IN NON HODGKINS LYMPHOMA VS UNLABELED ANTI B1
(131) IODINE-B1 RADIOIMMUNOTHERAPY OF ADVANCED NONHODGKIN'S LYMPHOMA
(131) IODINE-B1 RADIOIMMUNOTHERAPY OF ADVANCED NONHODGKIN'S LYMPHOMA
海外基金